Home/ Stocks/ RNXT

RenovoRx, Inc. Common Stock

RNXT XNAS

$1.08 +0.03 (+2.70%) ▲ 15-min delayed

Open

$1.11

High

$1.19

Low

$1.05

Volume

629.1K

Market Cap

$52.49M

About RenovoRx, Inc. Common Stock

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 10 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$213.0K	$-2,912,000	$-0.08
Q2 2025	$270.0K	$-2,895,000	$-0.08
Q1 2025	$103.0K	$-2,420,000	$-0.08
FY 2024	$43.0K	$-8,814,000	$-0.40

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for RNXT yet. Check out our latest market news or earnings calendar.

Get RNXT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on RenovoRx, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.